Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

7 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

GSK study: Ropinirole in RLS patients 101468/243 - Patient Rating Scales Baseline, Week 12, 24, 36, 48 and EW

- 30/07/17 - 1 modulo, 6 itemgroups, 24 elementi, 1 linguaggio
Itemgroups: Patient rated scale baseline, Patient rated scale week 12, Patient rated scale week 24, Patient rated scale week 36, Patient rated scale week 48, Patient rated scale early withdrawal
GSK study: Ropinirole in RLS patients 101468/243 - Patient Rating Scales Baseline, Week 12, 24, 36, 48 and EW Study ID: 101468/243 Clinical Study ID: 101468/243 Study Title: A 52 Week Open-Label Extension Study of the Long-Term Safety of Ropinirole in Subjects Suffering from Restless Legs Syndrome (RLS) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor:GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome

GSK study: Ropinirole in RLS patients 101468/243 - Early Withdrawal 1

- 30/07/17 - 1 modulo, 22 itemgroups, 49 elementi, 1 linguaggio
Itemgroups: Study medication record since last visit, RLS Rating scale, Vital signs, Medical procedures, Concomitant Medication, Adverse reaction, Patient rated scale, Healthcare resource utilisation - visits/contacts with physician, Healthcare resource utilisation - visits/contacts with physician, Healthcare resource utilisation - Visits/Contacts with other Paramedical Practitioners, Healthcare resource utilisation - Visits/Contacts with other Paramedical Practitioners, Healthcare resource utilisation - Hospitalisation, Healthcare resource utilisation - hospitalisation, Healthcare resource utilisation - accident & emergency / emergency room visits, Healthcare resource utilisation - accident & emergency / emergency room visits, Laboratory test, Urine dipstick, Pregnancy dipstick, Clinical global impression, Pregnancy information, Study conclusion, investigator signature
ONLY TO BE COMPLETED IF THE PATIENT IS WITHDRAWN Part 1 of EW1/ FU1: Early Withdrawal and Follow-up 101468/243 Study ID: 101468/243 Clinical Study ID: 101468/243 Study Title: A 52 Week Open-Label Extension Study of the Long-Term Safety of Ropinirole in Subjects Suffering from Restless Legs Syndrome (RLS) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor:GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome

GSK study: Ropinirole in RLS patients 101468/243 - Week 36

- 30/07/17 - 1 modulo, 30 itemgroups, 78 elementi, 1 linguaggio
Itemgroups: Study medication record since last visit, RLS Rating scale, Vital signs, Medical procedures, Concomitant Medication, Adverse reaction, Patient rated scale, Healthcare resource utilisation - visits/contacts with physician, Healthcare resource utilisation - visits/contacts with physician, Healthcare resource utilisation - Visits/Contacts with other Paramedical Practitioners, Healthcare resource utilisation - Visits/Contacts with other Paramedical Practitioners, Healthcare resource utilisation - Hospitalisation, Healthcare resource utilisation - hospitalisation, Healthcare resource utilisation - accident & emergency / emergency room visits, Healthcare resource utilisation - accident & emergency / emergency room visits, Clinical global impression, Instructions for the investigator, Clinical Global impression, Dose modification, Study medication and compliance record, Dose changes, Medical procedures, Medical procedures, Concomitant medication, concomitant medication, Non-serious adverse event, Non-serious adverse event, Pregnancy information, Study Subject Participation Status, investigator signature
Module 9A: Wk 36 to Cont/Wthd 101468/243 Study ID: 101468/243 Clinical Study ID: 101468/243 Study Title: A 52 Week Open-Label Extension Study of the Long-Term Safety of Ropinirole in Subjects Suffering from Restless Legs Syndrome (RLS) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor:GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome

GSK study: Ropinirole in RLS patients 101468/243 - Week 48

- 30/07/17 - 1 modulo, 30 itemgroups, 78 elementi, 1 linguaggio
Itemgroups: Study medication record since last visit, RLS Rating scale, Vital signs, Medical procedures, Concomitant Medication, Adverse reaction, Patient rated scale, Healthcare resource utilisation - visits/contacts with physician, Healthcare resource utilisation - visits/contacts with physician, Healthcare resource utilisation - Visits/Contacts with other Paramedical Practitioners, Healthcare resource utilisation - Visits/Contacts with other Paramedical Practitioners, Healthcare resource utilisation - Hospitalisation, Healthcare resource utilisation - hospitalisation, Healthcare resource utilisation - accident & emergency / emergency room visits, Healthcare resource utilisation - accident & emergency / emergency room visits, Clinical global impression, Instructions for the investigator, Clinical Global impression, Dose modification, Study medication and compliance record, Dose changes, Medical procedures, Medical procedures, Concomitant medication, concomitant medication, Non-serious adverse event, Non-serious adverse event, Pregnancy information, Study Subject Participation Status, investigator signature
Module 9B: Wk 36 to Cont/Wthd 101468/243 Study ID: 101468/243 Clinical Study ID: 101468/243 Study Title: A 52 Week Open-Label Extension Study of the Long-Term Safety of Ropinirole in Subjects Suffering from Restless Legs Syndrome (RLS) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor:GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome

GSK study: Ropinirole in RLS patients 101468/243 - Week 24

- 29/07/17 - 1 modulo, 33 itemgroups, 84 elementi, 1 linguaggio
Itemgroups: Study medication record since last visit, RLS Rating scale, Vital signs, Medical procedures, Concomitant Medication, Adverse reaction, Patient rated scale, Healthcare resource utilisation - visits/contacts with physician, Healthcare resource utilisation - visits/contacts with physician, Healthcare resource utilisation - Visits/Contacts with other Paramedical Practitioners, Healthcare resource utilisation - Visits/Contacts with other Paramedical Practitioners, Healthcare resource utilisation - Hospitalisation, Healthcare resource utilisation - hospitalisation, Healthcare resource utilisation - accident & emergency / emergency room visits, Healthcare resource utilisation - accident & emergency / emergency room visits, Laboratory test, Urine dipstick, Pregnancy dipstick, Clinical global impression, Instructions for the investigator, Clinical Global impression, Dose modification, Study medication and compliance record, Dose changes, Medical procedures, Medical procedures, Concomitant medication, concomitant medication, Non-serious adverse event, Non-serious adverse event, Pregnancy information, Study Subject Participation Status, investigator signature
Module 6B: Wk 24 to Cont/Wthd 101468/243 Study ID: 101468/243 Clinical Study ID: 101468/243 Study Title: A 52 Week Open-Label Extension Study of the Long-Term Safety of Ropinirole in Subjects Suffering from Restless Legs Syndrome (RLS) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor:GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome

GSK study: Ropinirole in RLS patients 101468/243 - Week 12

- 29/07/17 - 1 modulo, 30 itemgroups, 78 elementi, 1 linguaggio
Itemgroups: Study medication record since last visit, RLS Rating scale, Vital signs, Medical procedures, Concomitant Medication, Adverse reaction, Patient rated scale, Healthcare resource utilisation - visits/contacts with physician, Healthcare resource utilisation - visits/contacts with physician, Healthcare resource utilisation - Visits/Contacts with other Paramedical Practitioners, Healthcare resource utilisation - Visits/Contacts with other Paramedical Practitioners, Healthcare resource utilisation - Hospitalisation, Healthcare resource utilisation - hospitalisation, Healthcare resource utilisation - accident & emergency / emergency room visits, Healthcare resource utilisation - accident & emergency / emergency room visits, Clinical global impression, Instructions for the investigator, Clinical Global impression, Dose modification, Study medication and compliance record, Dose changes, Medical procedures, Medical procedures, Concomitant medication, concomitant medication, Non-serious adverse event, Non-serious adverse event, Pregnancy information, Study Subject Participation Status, investigator signature
Module 6A: Wk 12 to Cont/Wthd 101468/243 Study ID: 101468/243 Clinical Study ID: 101468/243 Study Title: A 52 Week Open-Label Extension Study of the Long-Term Safety of Ropinirole in Subjects Suffering from Restless Legs Syndrome (RLS) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor:GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome

Johns Hopkins RLS QOL Questionnaire (RLSQOL) Ropinirole Restless Legs Syndrom NCT00355641 - Johns Hopkins RLS QOL Questionnaire

- 05/08/17 - 1 modulo, 1 ItemGroup, 1 elemento, 1 linguaggio
ItemGroup: Assessment of quality of life
Study part: Johns Hopkins RLS QOL Questionnaire. A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients with Restless Legs Syndrome (RLS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Clinicaltrials.gov Identifier: NCT00355641. Phase: phase 3. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP, Zygara; Zygara, ZIPEREVE, ZEPREVE, Requip Depot, REQUIP, REPREVE, Modutab, ADARTREL. Study Indication : Restless Legs Syndrome. Study ID: 101468/206. Clinical Study ID: 101468/206.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial